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Abstract This review article classifies the various adverse
reactions arising from intra-articular injections by severity,
diagnostic category, and whether they are due to cortico-
steroid, local anesthetic or viscosupplementation injections.
Life-threatening and serious adverse events from intra-
articular injections are rare and range from local complica-
tions to systemic afflictions. Measures to reduce the
likelihood of an adverse event occurring are outlined and
patients with significant features in their clinical histories,
predisposing them to adverse events, are highlighted.
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Introduction
Injections of local anesthetics into spinal and peripheral
joints have been used effectively for many years to help
localize the source of a patient’s pain. These diagnostic
injections, using primarily lidocaine hydrochloride, bupiva-
caine hydrochloride or ropivacaine hydrochloride, have a
substantial body of research to support their value,
particularly when done under imaging guidance [1–12].
Therapeutic joint injections, consisting of either a cortico-
steroid or a hyaluronic acid product (viscosupplementation)
along with local anesthetics, have also been used for several
years [1–4, 6–11, 13–18], although the level of evidence
supporting this therapy is not quite as strong [2–6, 11, 13–
16]. Arthrography consists of the injection of a contrast
agent into a joint and is performed for both diagnostic and
therapeutic purposes. It is often used during imaging-
guided procedures to facilitate accurate needle placement
[1, 17].
Several papers have reported the various adverse events
that may result from diagnostic and therapeutic musculo-
skeletal injections, including arthrography, and it is gener-
ally acknowledged that adverse events are uncommon,
being reported in 2.4% to 12% of patients. Most of these
adverse events are very mild and self-limiting [17–20].
Severe adverse events associated specifically with arthrog-
raphy have been reported to be exceedingly rare, occurring
in approximately 0.03% of patients as determined in a
large, retrospective, questionnaire-based study [20]. Ac-
knowledging that diagnostic and therapeutic joint injections
are usually very safe and effective, the purpose of this paper
is to briefly outline and categorize the possible adverse
events that have been reported and to identify practices that
may reduce the likelihood of certain events occurring.
Extra-articular injections
Although many physicians inject corticosteroids and/or local
anesthetics into various joints in their own offices, current
guidelines and standards of practice recommend that these
injections should be done using imaging guidance, including
the use of a contrast agent, to visualize and facilitate correct
placement of the needle into the targeted joint [1–13, 17, 21].
The shoulder and knee joints are two areas commonly
injected in medical offices without the use of imaging
guidance [1, 17, 21–27]. Studies examining the accuracy of
C. Peterson (*) : J. Hodler
Radiology, Orthopaedic University Hospital of Balgrist,
Forchstrasse 340,
8008 Zürich, Switzerland
e-mail: cynthia.peterson@balgrist.ch
Skeletal Radiol (2011) 40:5–12
DOI 10.1007/s00256-009-0839-y
intended intra-articular injections into these joints, performed
either with or without imaging guidance, clearly demonstrate
that the accuracy of hitting the intended target is poor if
imaging is not used, even when the confidence of the
clinician that the correct joint space or bursa has been
reached is high [1, 17, 21–27]. Using fluoroscopic imaging
to guide needle placement, 93% of knee injections are intra-
articular, compared with only 66% if a single radiograph is
used to evaluate accuracy [23]. The accuracy of entering the
knee joint without any imaging guidance has not been
ascertained. However, without the use of diagnostic imaging,
at best only 69–76% of subacromial bursal injections hit
their intended target [22] with many of these also injecting
unintended extra-articular surrounding structures (Fig. 1).
Other studies evaluating the accuracy of needle placement
for the glenohumeral and subacromial regions of the
shoulder report much worse results for hitting the intended
target. Only 27–37% of patients benefitted from injection
into the correct anatomical site when imaging guidance was
not used [24, 25].
The importance of accurately placing the needle into the
intended joint space is supported by studies demonstrating
that not only are the clinical outcomes for patients much
better when the medication is injected into the desired
target joint [25, 26], but the risk of certain adverse events is
reduced [1, 28]. Missing the intended target and injecting
into periarticular structures increases the risk of tendon
tears, soft tissue atrophy, skin atrophy, depigmentation, and
injury to adjacent structures [1, 28]. Therefore, one way to
reduce the likelihood of an adverse event from joint
injections is to follow practice guidelines and perform
these under appropriate imaging guidance (Fig. 2).
Imaging-guided therapeutic injections are usually per-
formed using fluoroscopy, ultrasound, computed tomogra-
phy (CT), and most recently, magnetic resonance imaging
(MRI) [1–13, 17, 21, 29–32]. Ultrasound shows certain
advantages over fluoroscopy, particularly for peripheral
joints and related soft tissues [29–31], as it allows
avoidance of neurovascular and tendinous structures in the
vicinity of the desired target site as well as demonstrating
fluid collections. Ultrasound guidance has also been shown
to be more accurate than fluoroscopy in allowing placement
of the needle into the shoulder joint [30].
Classification of adverse events
Several reactions have been reported in the literature as
adverse events following not only blind injections, but also
imaging-guided arthrography or diagnostic and therapeutic
joint injections. Most can be categorized as mild, moderate,
severe or life threatening, although such a classification
system is somewhat subjective with overlap between
categories for a few conditions (Tables 1, 2) [33–75]. The
life-threatening adverse reactions include air embolism,
anaphylactic reactions, hypotension, vasomotor collapse,
laryngeal edema, adrenal insufficiency (only linked with
corticosteroid injections), and apnea [17, 20, 33, 53, 65–
68]. Brain and spinal cord infarctions have been reported
when particulate corticosteroids are used during cervical
transforaminal injections [12] and for this reason, cervical
transforaminal injections have been discontinued at this
facility. Life-threatening reactions that can specifically
result from local anesthetic injections include central
nervous system and cardiac toxicity if the local anesthetic
is inadvertently administered into the vascular system or
intrathecally [12]. The threshold dose needed to cause this
devastating adverse event appears to be much lower if
bupivacaine is used rather than lidocaine, as bupivacaine is
more cardiotoxic [12]. The life-threatening adverse reac-
tions are so rare, however, that the literature is mostly
limited to case reports.
Fig. 1 Imaging-guided injection
attempting to target the
subacromial bursa. Contrast
medium injection demonstrates
that the needle is not in the
bursa. The needle can thus be
repositioned prior to injection
of medication
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Severe reactions are also very uncommon and include
those that may result in marked limitation in activity and/or
require medical intervention and possible hospitalization.
For corticosteroid injections such reactions include septic
arthritis, seizures, avascular necrosis, a Charcot-like ar-
thropathy, tendon tears, reactivation of complex regional
pain syndrome, and damage to adjacent structures such as
nerves, vessels or muscles [34, 55, 56, 68].
Moderate reactions, while also rare, are many and
varied, with most requiring limited or no medical interven-
tion and resulting in mild to moderate limitation in activity.
For injections containing corticosteroids, moderate reac-
tions may include elevated blood pressure, elevated blood
sugar, transient hypophosphatemia, Cushing’s syndrome,
less severe damage to adjacent structures such as vessels,
tendons or nerves, bleeding into the joint, skin necrosis,
flare reactions, Tachon syndrome (intense lumbar and/or
thoracic pain a few minutes after injection with rapid
subsidence of the pain), dysphonia, steroid-induced psy-
chosis (transient), urticaria, insufficiency fractures, and
vasovagal reactions [33, 34, 46–50, 54, 59, 62]. Local
anesthetics may cause a moderate adverse reaction known
as skeletal muscle toxicity. This usually results in complete
recovery [12].
Looking specifically at viscosupplementation (hyalur-
onic acid derivatives), which is used as a treatment for
patients with osteoarthritis, particularly of the knee, the
severe adverse events reported include septic arthritis,
seizures, crystal deposition disease, injury to adjacent
structures, and reactivation of complex regional pain
Fig. 2 CT-guided sternoclavicular (SC) joint injections. Contrast
medium visualized in the left SC joint from the first injection confirms
correct anatomical placement. The needle is now visualized in the
right SC joint. The close proximity of important large vascular
structures behind the sternum highlights the necessity of using
imaging guidance
Table 1 Possible adverse reactions from corticosteroid joint injections
Mild Moderate (all are very rare) Severe (all are very rare) Life-threatening (all are very rare)
Local paina
(most common)
Elevated blood pressure Septic arthritis Hypotension
Mild local redness
without heata
Elevated blood sugar (transient) Reactivation of complex
regional pain syndrome
Air embolism
Local tissue atrophy Cushing’s syndrome Seizures Laryngeal edema
Cellulitis Hypophosphatemia (transient) Avascular necrosis Apnea
Pressure in jointa Abnormal uterine bleeding Charcot-like arthropathy Anaphylactic reaction and
vasomotor collapse
Hypopigmentation Rupture of local tendons/fascia Rupture of local tendons/fascia Adrenal insufficiency
Flush reaction Damage to local muscles
or other adjacent structures
(nerves, vessels)
Damage to local muscle or
other adjacent structures
(could be moderate or severe)
Spinal cord or brain infarct
from particulate steroids in
cervical epidural block procedure
Temporary
paresthesia of
the joint (e.g. hip)
Hemarthrosis
Vasovagal reaction
Skin necrosis
Tachon syndrome (transient)
Dysphonia
Steroid-induced psychosis
(transient)
Flare reactions
Urticaria
Herpes zoster
Insufficiency fracture
a Common
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syndrome [34, 51–53, 55–57, 67, 72, 73]. Viscosupple-
mentation injections appear to provide a shorter list of
moderate adverse events than corticosteroid injections.
These include acute pseudoseptic arthritis (described later),
granulomatous inflammation, hemarthrosis, vertigo, urticar-
ia, and injury to adjacent structures.
Mild adverse reactions are by far the most common of
the post-injection events, require no medical intervention,
and are transient. The most frequent mild reaction is local
pain. Other minor reactions include pressure in the joint,
slight swelling, local tissue atrophy, urticaria, rash, facial or
general flushing, hypopigmentation (which usually normal-
izes over a period of 12 months), reactivation of herpes
zoster, flare reactions (explained in a later section), and
mild cellulitis [12, 35, 36, 39, 54, 60, 61, 63, 64, 68, 69, 74,
75]. Some of these moderate, severe, and life-threatening
reactions deserve more attention and will be briefly
discussed in categories.
Injection-induced arthropathies
In 1985, Newberg et al. [33] reported that the most
common adverse reaction following arthrography injections
was transient sterile chemical synovitis. It appears from the
recent literature that this may now be known as sterile
Table 2 Possible adverse reactions from viscosupplementation joint injections
Mild Moderate (all are rare) Severe (all are very rare) Life-threatening
(all very rare)
Local paina Acute pseudoseptic arthritis
(aka “‘flare” reaction or chemical synovitis)
Septic arthritis Hypotension
Transient inflammatory responsea Granulomatous inflammation Reactivation of complex
regional pain syndrome
Air embolism
Local tissue atrophy Hemarthrosis Seizures Anaphylactic reaction
Cramps and restless legs Vertigo Crystal deposition arthritis Laryngeal edema
Adjacent structure injury (nerves, vessels) Adjacent structure injury
(nerves, vessels)
Apnea
Urticaria, puritus Vasomotor collapse
a Common
Table 3 Recommended actions to reduce the risk of adverse events
Recommended action Adverse event risk effect
Use imaging guidance. Reduced risk of injuring adjacent structures (nerves, vessels,
tendons, etc). Reduced risk of granulomatous reaction from HA
products. More effective therapeutic action of drug if in the joint.
Use HA products of lower molecular weight and
not from animal sources.
Decreased risk of ‘flare reactions or pseudosepsis.
Check for history of CPPD (calcium pyrophosphate
crystal deposition) disease.
Viscosupplementation injections may cause an acute flare-up
of CPPD (pseudogout) in these patients.
Don’t inject HA product if chondrocalcinosis
visible on routine radiographs.
Apply careful sterile technique and do not inject
if overlying skin infection or psoriasis.
Reduced risk of septic arthritis.
Determine whether or not the patient is
immunocompromised.
These patients have an increased risk of septic arthritis,
herpes zoster.
Check to determine if and when joint replacement
surgery is planned. Reconsider use of intra-articular
steroids in patients who are likely candidates for joint
replacement surgery in the near future. Inform patients
of potential risks if injections used.
Preoperative intra-articular steroid injections appear to
significantly increase risk of post-operative deep infections.
Determine whether or not the patient has diabetes. Hyperglycemia cannot be avoided, but patients must be
informed to reduce the anxiety level and to better control
their blood sugar during this time.
Inform diabetic patients that their blood sugar levels
will rise significantly shortly after injection and will
remain high for a few days.
Determine whether or not this patient is a child with
inflammatory arthropathy who needs multiple
steroid injections over time.
These patients are at increased risk of Cushing’s syndrome.
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synovitis, the “flare reaction” or “pseudosepsis” due to the
clinical presentation being similar to true joint sepsis, but
supposedly without micro-organisms [1, 37, 38]. However,
the descriptions of flare reactions and pseudosepsis in the
literature are inconsistent and overlapping. Some authors
describe the flare reaction as simply a delayed post-
injection transient increase in pain of at least 2 points on
a 0–10 visual analogue scale [39], while others use the
terms flare reaction and pseudosepsis interchangeably,
describing the symptoms as severe pain, warmth, joint
swelling, and effusion [37], symptoms that most definitely
mimic true septic arthritis. Flare reactions or pseudosepsis
are most appropriately categorized as a moderate adverse
event and are self limiting in most cases. They appear to be
more common when hyaluronic acid products (viscosup-
plementation) are injected rather than with corticosteroid
injections [37, 38, 40]. It is suggested that hyaluronic acid
products of higher molecular weight, such as Hylan GF-20
(Synvisc; Genzyme, Neu-Isenburg, Germany), may be
more prone to producing flare reactions and that those that
do not contain components from animal sources may be a
better alternative [38].
Adding further confusion to the diagnosis of a non-
infective adverse event following hyaluronic acid injections
is the condition labeled “granulomatous synovitis” [41, 42].
The descriptions of these granulomatous reactions in the
literature appear nearly identical to those of flare reactions
and pseudosepsis. The patient’s symptoms are joint pain,
swelling, and warmth developing within 48 h of injection,
gradually resolving without treatment. It is suggested that
these granulomatous reactions are due to injection of
hyaluronic acid (viscosupplementation) into an adjacent
fat pad or subsynovial tissue [37] causing a foreign-body
granulomatous inflammation [44]. This adverse event has
been reported primarily in the knee as this is the joint where
viscosupplementation is most commonly injected [37, 43,
44] in patients suffering from osteoarthritis.
The other non-infective arthritic adverse event that
may be induced from hyaluronic acid injections in
particular is an acute attack of calcium pyrophosphate
dihydrate crystal arthropathy (CPPD or pseudogout) [43,
44]. It is suggested that viscosupplementation injections
should not be given to patients with chondrocalcinosis
visible on routine radiographs.
The most serious and feared injection-induced arthrop-
athy is septic arthritis with an estimated occurrence rate of 1
in 10,000 to 1 in 50,000 injections [26, 45, 70, 71]. The
rapid and irreversible joint destruction caused by pyogenic
micro-organisms is the reason why this is classified as a
serious adverse event. Although any joint injection has an
inherent risk of microbial contamination, it is hypothesized
that the risk of septic arthritis might be higher in patients
receiving corticosteroid injections compared with those
receiving viscosupplementation, as corticosteroids are
known to have an immunosuppressive effect [71]. Such
effects are better known when the steroids are taken orally,
however. Obviously, using a sterile technique when
performing joint injections is critical and considered
standard practice for reducing this risk.
Two retrospective comparative studies found that intra-
articular corticosteroid injections into the knees or hips of
patients likely to receive joint replacements in the future
significantly increased their risk of deep infections of these
joints post-operatively compared with patients who did not
have these injections [72, 73]. For hip joints the rate of
deep post-operative infection was described by the authors
as “disturbing,” being 10% of injected patients compared
with only 1% of patients who did not receive intra-articular
corticosteroid injections pre-operatively [72]. Knee replace-
ment patients had a 22.2% chance of wound complications
after surgery if they had received intra-articular steroid
injections pre-operatively [73]. Neither of these studies
described the time period between the patient receiving the
steroid injection and the joint replacement surgeries or the
number of steroid injections received pre-operatively.
Prospective comparative studies on large patient numbers,
including the number of injections given and the time frame
between the injections and the surgery are indicated to
further evaluate these findings. Papavasiliou et al. [73]
speculate that the steroid agent might become trapped in the
joint and therefore not fully dissolve, thus creating a local
reduction in immunity. Although it is very common for
osteoarthritis patients to receive intra-articular steroid
injections to improve their quality of life and to postpone
joint replacement surgeries, clinicians administering intra-
articular steroid injections should be aware of this potential
risk and perhaps include this information in their informed
consent procedures. Others may want to weigh the
likelihood of the patient needing a knee or hip joint
replacement in the near future before performing these
procedures in certain situations [72, 73].
Systemic reactions after local intra-articular injection
The reporting of a variety of systemic reactions after local
musculoskeletal injections of corticosteroids demonstrates
that these injections have effects beyond the local joint.
Intra-articular corticosteroids are rapidly absorbed into the
circulation, reaching their maximum blood levels 3–6 h
after injection [59]. Patients with controlled type II diabetes
who receive an intra-articular steroid injection of methyl-
prednisolone acetate to the knee will have a significant
increase in their blood sugar as early as 2–4 h after injection
and lasting as long as 5 days [48]. A rare, transient, but
initially frightening systemic complication of intra-articular
Skeletal Radiol (2011) 40:5–12 9
corticosteroid injection is hypophosphatemia [59]. Symp-
toms include transient paresthesia and weakness of the
limbs and dysarthria, coming on hours after the injection
[59]. The hypothesized mechanism for this reaction
described in the case report was either increased sensitivity
to the effects of glucocorticoids or a reduced threshold to
the physiological consequences of hypophosphatemia [59].
Secondary Cushing’s syndrome, due to intra-articular
corticosteroid injections, has also been reported, particular-
ly in pediatric patients with juvenile chronic arthritis who
need repeated injections over a prolonged period of time
[49–51]. This has also been reported after a single
corticosteroid injection in HIV-infected patients who are
being treated with the antiretroviral drug ritonavir [52]. A
related, but far more serious systemic complication due to
intra-articular corticosteroid injections is adrenal insuffi-
ciency and failure [51–53]. If unrecognized, this can lead to
adrenal crisis, collapse, hypotension, and death [51]. Of the
cases reported in the literature, the corticosteroid implicated
in each patient was triamcinolone acetonide [51–53].
Intra-articular and epidural corticosteroid injections have
also been linked with a flushing reaction of primarily the
face and upper trunk with a generalized reaction noted in
some patients [74, 75]. This flushing reaction includes
redness of the skin and a sensation of warmth, with no other
systemic effects, and is reported to be more common in
women [74, 75]. While it has occurred more commonly
when triamcinolone is injected, methylprednisolone injec-
tions have also produced this effect [74]. The reaction is
self-limiting, with the administration of diphenhydramine
reducing the duration of this reaction [74].
Prevention of particular adverse events
Table 3 summarizes the recommendations for reducing the
risk of adverse events from intra-articular injections. Using
a careful sterile technique when performing joint injections
is standard practice and reduces, but does not totally
eliminate, the risk of joint infection [1, 17, 76]. Critical
components of the sterile technique procedure require that
the doctor wear a mask (particularly if he/she has an upper
respiratory tract infection), disinfect the hands and wear
sterile gloves, disinfect the skin using either an iodine-
based solution or alcohol, and drape the area with sterile
towels [1, 17, 76]. Avoiding injections when overlying skin
infections, wounds or inflammatory diseases such as
psoriasis are present is also standard practice to avoid
inoculating the joint with micro-organisms. Patients who
are likely candidates for joint replacement surgery should
be informed of the risks of serious post-operative infections
if they receive an intra-articular corticosteroid injection pre-
operatively. Additionally, clinicians should carefully con-
sider whether or not these patients should be treated with
intra-articular corticosteroids prior to surgery [72, 73].
Flare reactions or pseudosepsis may be decreased by using
hyaluronic acid preparations that are of lower molecular
weight and are not derived from animal products [38]. As
several cases of hyaluronic acid-induced acute CPPD
(pseudogout) have been reported [43, 44], it is suggested
that this treatment be avoided if chondrocalcinosis is already
visualized on routine radiographs of the involved joint to
prevent acute exacerbation of the symptoms.
Systemic reactions other than hyperglycemia in diabetics
are extremely rare and precautions cannot be taken at this
point in time to reduce their likelihood. However, the signs
and symptoms of adrenal insufficiency and hypophosphate-
mia must be readily recognized so that appropriate confirming
diagnostic tests and treatment or reassurance can be provided
to the patient [51–53, 59]. Diabetic patients must be informed
about the likely changes in their blood sugar levels and that
these may last for a few days after injection.
Finally, using imaging guidance for diagnostic and
therapeutic joint injections is imperative to reduce the risk
of damaging adjacent structures as well as achieving the
best clinical effect from the medication reaching the
intended target. Additionally, the risk of granulomatous
synovitis secondary to extra-articular injection of hyalur-
onic acid will be reduced if imaging guidance is applied.
Because triamcinolone hexacetonide is more likely to cause
local tissue necrosis, tendon rupture, and calcification if
injected in an extra-articular location, it is imperative that
imaging guidance be used when this corticosteroid is
injected [12]. It is also suggested that triamcinolone
hexacetonide, a very effective steroid with a relatively long
clinical benefit, be administered by a more experienced
radiologist [12].
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